Scientific Advice from EMA is due the first week of March

As previously announced, Double Bond Pharmaceutical has submitted a Protocol Assistance request to EMA to obtain scientific advice regarding SI-053 . The advice from EMA will be based on a number of questions from DBP mainly regarding the preclinical development of SI-053 and the planned Phase I trial in glioblastoma patients. DBP expects useful advice for the product development. Yesterday, DBP were noticed that a final advice letter will be obtained from EMA during the first week in March. The Protocol Assistance is free of charge